🚀 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗱 𝗮𝘁 𝗧𝗦 𝗩𝗮𝘀𝗰𝘂𝗹𝗮𝗿

We are proud to announce that TS Vascular has successfully dosed its first patient with a 3 hour infusion of sodium thiosulphate (STS) in STS-001, our first explorative clinical study.

This important milestone will enable that our oral STS program will be initiated in the clinic soon and represents a key step towards addressing significant unmet need, oral dosing, in various vascular diseases, starting with Raynaud’s Phenomenon.

“𝘈 𝘥𝘦𝘧𝘪𝘯𝘪𝘯𝘨 𝘮𝘰𝘮𝘦𝘯𝘵 𝘧𝘰𝘳 𝘛𝘚 𝘝𝘢𝘴𝘤𝘶𝘭𝘢𝘳 𝘢𝘯𝘥 𝘢 𝘵𝘦𝘴𝘵𝘢𝘮𝘦𝘯𝘵 𝘵𝘰 𝘴𝘵𝘳𝘰𝘯𝘨 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯,” said Pierre Peeters, CEO. “𝘞𝘦 𝘢𝘳𝘦 𝘨𝘳𝘢𝘵𝘦𝘧𝘶𝘭 𝘵𝘰 𝘰𝘶𝘳 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴 𝘊𝘛𝘊 𝘕𝘦𝘵𝘩𝘦𝘳𝘭𝘢𝘯𝘥𝘴 𝘢𝘯𝘥 𝘜𝘔𝘊𝘎 𝘧𝘰𝘳 𝘩𝘦𝘭𝘱𝘪𝘯𝘨 𝘣𝘳𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘱𝘳𝘰𝘨𝘳𝘢𝘮 𝘪𝘯𝘵𝘰 𝘵𝘩𝘦 𝘤𝘭𝘪𝘯𝘪𝘤.”
𝗠𝗼𝗿𝗲 𝘁𝗼 𝗰𝗼𝗺𝗲.